在美国，丙型肝炎病毒相关的肝细胞癌的发病率和死亡率在少数族裔中最高。社会经济限制在不平等待遇中发挥着重要作用。我们评估了克服治疗障碍的人群中种族/族裔与结果之间的关联。我们报告了一项回顾性队列研究，研究对象为 2015 年至 2019 年美国肝细胞癌肝移植联盟 20 个机构的 666 名患者，这些患者患有丙型肝炎病毒相关肝细胞癌完成直接抗病毒治疗并接受肝移植的癌症患者。如果患者之前接受过肝移植、肝细胞癌复发、之前没有针对肝脏的治疗，或者种族/民族数据不可用，则患者被排除。患者按种族/民族进行分层。主要结局是无复发生存率和总生存率，次要结局是主要术后并发症。种族/民族与 5 年无复发生存率的差异无关（白人 90%，黑人 88%，西班牙裔 92%，其他 87） %；p = 0.85）、总生存率（白人 85%、黑人 84%、西班牙裔 84%、其他 93%；p = 0.70）或主要术后并发症。种族/民族与这些人群中较差的肿瘤或术后结果无关他们完成了直接抗病毒治疗并接受了肝移植，这表明克服社会经济限制可以使不同种族/族裔群体的结果平等。消除阻碍少数群体获得护理的障碍必须成为当务之急。© 2024。肿瘤外科学会。

In the United States, hepatitis C virus-associated hepatocellular carcinoma incidence and mortality are highest among minorities. Socioeconomic constraints play a major role in inequitable treatment. We evaluated the association between race/ethnicity and outcomes in a population that overcame treatment barriers.We report a retrospective cohort study of 666 patients across 20 institutions in the United States Hepatocellular Carcinoma Liver Transplantation Consortium from 2015 to 2019 with hepatitis C virus-associated hepatocellular carcinoma who completed direct-acting antiviral therapy and underwent liver transplantation. Patients were excluded if they had a prior liver transplantation, hepatocellular carcinoma recurrence, no prior liver-directed therapy, or if race/ethnicity data were unavailable. Patients were stratified by race/ethnicity. Primary outcomes were recurrence-free survival and overall survival, and secondary outcome was major postoperative complication.Race/ethnicity was not associated with differences in 5-year recurrence-free survival (White 90%, Black 88%, Hispanic 92%, Other 87%; p = 0.85), overall survival (White 85%, Black 84%, Hispanic 84%, Other 93%; p = 0.70), or major postoperative complication.Race/ethnicity was not associated with worse oncologic or postoperative outcomes among those who completed direct-acting antiviral therapy and underwent liver transplantation, suggesting that overcoming socioeconomic constraints equalizes outcomes across racial/ethnic groups. Eliminating barriers that prohibit care access among minorities must be a priority.© 2024. Society of Surgical Oncology.